Physicochemical Properties
| Molecular Formula | C19H18FNO3 |
| Molecular Weight | 327.35 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | AChE 5.3 μM (IC50) BChE 12.4 μM (IC50) hMAO-B 1.9 μM (IC50) |
| ln Vitro | Compound 4b (AChE/BuChE/MAO-B-IN-2)(5, 10, 20 μmol/L, 2 h) significantly reduces PC12 cell damage caused by Aβ1-42[1]. AChE/BuChE/MAO-B-IN-2 (1 mg/mL for incubation, 0, 0.5, 1, 1.5, 2, 3 h) has good and stable properties in rat liver microsome sex, plasma, and artificial gastrointestinal fluid[1]. |
| ln Vivo | Compound 4b, AChE/BuChE/MAO-B-IN-2 (0.0049, 0.0195, and 0.078 μg/mL for treatment, 10min), has been shown to considerably enhance the zebrafish AD model produced by ACAL3 in terms of responsiveness and movement abnormalities [1]. |
| Cell Assay |
Cell Viability Assay[1] Cell Types: PC12 cell Tested Concentrations: 5, 10, 20 μmol/L Incubation Duration: 2 h Experimental Results: Increased the cell viability to 70.9 %, 75.0 %(p < 0.05) and 79.7 %(p < 0.01 ), respectively, in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: AlCl3-induced zebrafish AD[1] Doses: 0.0049, 0.0195 and 0.078 μg/mL Route of Administration: incubation Experimental Results: Presented the best distance velocity with 0.0195 μg/mL under the dark condition, with 0.0049 μg/mL under the light condition and with 0.0195 μg/mL under the alternating dark light. |
| References |
[1]. Development of the "hidden" multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer's disease. Eur J Med Chem. 2023 May 5;251:115253. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0548 mL | 15.2742 mL | 30.5483 mL | |
| 5 mM | 0.6110 mL | 3.0548 mL | 6.1097 mL | |
| 10 mM | 0.3055 mL | 1.5274 mL | 3.0548 mL |